Document is current

Article History

Received: 4 August 2021

Accepted: 6 February 2022

First Online: 4 March 2022

Declarations

:

: Not applicable.

: Not applicable.

: HL reports a Grant from NHMRC during the conduct of the study. HL and JD report fees from AveXis, Anavex, Newron and GW outside the submitted work and with all renumeration paid to their Institution. MS reports Grant support from Novartis, Roche, Pfizer, Ipsen, LAM Therapeutics, Biogen, Bridgbio and Quadrant Biosciences outside the submitted work. He has served on Scientific Advisory Boards for Sage, Novartis, Roche, Aeovian, Regenxbio, Alkermes and Takeda. TB reports Grants from NIH/NICHD, Grants from Childrens Hospital Colorado Foundation and Grants from Rocky Mountain Rett Association during the conduct of the study. He reports Grants from NIH, and consultancy withTakeda/Ovid, Marinus, Avexis, Greenwich Biosciences, Acadia/Neuren, the Rett Syndrome Research Trust and the International Foundation for CDKL5 Research outside the submitted work; all remuneration has been made to his department. RS reports Grant support from NIH, Ultragenyx, Penn Medicine Orphan Disease Center CDKL5 Program of Excellence, and the Texas Children’s Hospital Stedman West Endowed Fund in Neurological Research outside of the submitted work. WG reports Grant support from NHMRC and Luminesce Alliance outside of the submitted work. We do not have any competing interests relating to the submitted work.